Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Yue Ren(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Victoria Patterson(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Liam Hackett(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Adam J. Olszewski(Memorial Hospital of Rhode Island), Steve Lo(Stamford Hospital), Jeremy Zhang(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), Heather A. Walker(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Matthew Weinstock(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k